LIDDS AB (publ) announced that Nina Herne will assume the role of chief executive officer for LIDDS, effective April 19, 2021. Nina Herne has successfully held multiple senior positions in global pharmaceutical companies, most recently at Chiesi Group where she built a biotech operation and managed the company’s Swedish R&D site. Nina brings a wide range of experience from business development and licensing, R&D, operations, strategy development and international stakeholder management from smaller organizations like Zymenex (Managing Director for Sweden and Denmark) and NeuroNova, as well as larger companies like Chiesi, SOBI and NovoZymes (NovoNordisk). Monica will remain as CEO until Nina is in place.